Hemophilia B — Deal Benchmarks & Valuation
Market Analysis
Hemophilia B is one of the most actively transacted indications in rare disease licensing. Phase 2 deals for hemophilia b carry a median total deal value of $1.8B, with upfront payments ranging from $158M to $496M. The recommended deal structure allocates approximately 18% to upfront payments and 82% to milestones.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for hemophilia b licensing?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.
Start Calculating